INTRODUCTION
Background. TNP-470 (AGM-1470) is a potent inhibitor of angiogenesis with potential therapeutic applications in neoplastic and angio-proliferative diseases. This study evaluated its effect on cutaneous wound healing in a murine dorsal excisional wound modelo Materials and methods. Full-thickness wounds (1.60 cm 2) were created on the dorsum of homozygous/ hairless mice (7 to 9 weeks). Wound areas were measured on alternate days for 16 days. Experimental groups consisted of (1) Results. TNP-470 administration significantly decreased wound healing in a dose-dependent manner versus controls (P < .05). The 5.0 mg/kg concentration yielded the greatest effect by maintaining an average wound area 20.4% greater than controls and a marked delay in wound healing on H&E staining. Alternateday dosing was as effective as consecutive day administration. Minocycline did not augment the wound healing inhibition of TNP-470. Coadministration of TNP-470 and bFGF eliminated any rate-altering effect of TNP-470 upon wound healing and resulted in wound areas similar to controls.
Wound healing involves a complex cascade of events that ultimately restores the structural integrity of an organism [1] . This process proceeds through a series of coordinated events that usually produces a scar both functionally proficient and cosmetically acceptable. In the majority of clinical settings, the rate of wound healing is appropriate to enable coordinated and efficient repair. Angiogenesis is critical to the delivery of reparative cells and growth factors central to the healing process. Angiogenesis inhibitors are currently being investigated as agents to treat pathogenic conditions in which angiogenesis is integral, such as neoplasia. Among the many agents that have been found to have antiangiogenic properties [2] , TNP-470 (AGM-1470) is among the most extensively studied [3] [4] [5] [6] [7] [8] [9] [10] .
TNP-470 is a derivative of fumagillin isolated from the fungus Aspergillus fumigatus fresenius [3] , which was initially discovered during contamination of endothelif!l cell cultures [4] . TNP-470 has been demonstrated to serve as an effective angiogenesis inhibitor by inhibiting endothelial cell proliferation [5] , capillary endothelial cell migration [6] , and capillary tube for- (1)TNP-470 alone  Dosing regimen Days O, 2, and 4 Experimental Group 1 (n = 7) Experimental Group 2 (n = 7) Experimental Group 3 (n = 9) Control group (n = 17) Dosing regimen Days O through 6 Experimental Group 1 (n = 7) Experimental Group 2 (n = 7) Experimental Group 3 (n = 7) Control group (n = 7) (2) TNP-470 + minocycline Experimental Group 1 (n = 7) Control Group 1 (n = 7) Experimental Group 2 (n = 7) Control group 2 (n = 7) (3) TNP-470 + exogenous bFGF Experimental Group 1 (n = 7) Experimental Group 2 (n = 7) Experimental Group 3 (n = 7) Control group (n = 6) Male homozygous hairless mice (Jackson Laboratories, Bar Harbor, ME) between the ages of6 to 8 weeks were housed individually in a controlled environment with normal light-dark cycles and a constant temperature maintained between 78 to 82.C. The mice were acclimatized to their environment for 1 week before fue study began and were provided water and rodent chow ad libitum. Each mouse was individually anesthetized with inhaled Metofane (Pitman-Moore, Mundelein, IL) and immediately weighed postanesthesia. AlI animals were handled in accordance with the guidelines established by the University of Louisville Animal CaTe and Use Committee.
mation [7] . The efficacy of TNP-470 as an angiogenesis inhibitor has been demonstrated experimentally for the treatment of hemangiomas [4] , corneal neovascularization [8] , and primary tumors and metastatic disease [5, 9] . Additionally, it has been demonstrated that the antiangiogenic effects of TNP-470 can be augmented with the addition of minocycline in a murine Lewis lung carcinoma model [10] . It has been speculated that the inhibitory effect of TNP-470 on angiogenesis is due to an inhibition of the actions of basic fibroblast growth factor (bFGF) [8, 11] .
The roles ofbFGF are well documented in the wound healing process. Basic FGF is a chemoattractant for numerous cell types [12] , a potent mitogen for angiogenesis [13] , and an activator of wound contraction [14] . Additionally, exogenous administration of bFGF has been shown to increase the rate of wound closure [15] ; therefore, inhibition of the effect of bFGF, used with TNP-470, could potentially modulate the wound healing process. We sought to investigate what effects an angiogenesis inhibitor would have on a wound left to heal by secondary intention and whether these effects could be modified with the simultaneous administration of additional agents.
Surgical Manipulation
On Day o of the study, a full-thickness wound, including the panniculus carnosus, was excised from the dorsum of each mouse. Using a standard template, a 1.60-cm2 circular defect was outlined 2.0 cm from the nape ofthe animal's neck using a fine-tipped marking peno The defect was created by elevating the skin and panniculus camosus in the center of the outlined defect using nontoothed forceps, followed by excision of the outlined area using microdissecting scissors. The wounds were continuously covered with both a nonadherent dressing (petrolatum gauze [Kendall-Curity, Mansfield, MA] or DuoDerm gel [Convatec, Princeton, NJ]) and an occlusive dressing (Tegaderm, 3M, Sto Paul, MN). The wounds were allowed to clase by secondary intention.
METHODS

Data Acquisition and Analysis
Each animal was placed on its ventral surface with all limbs extended laterally for wound area measurements':, The area of the wound was viewed at a final magnification of 25 x using a color video camera (Mintron, OS-70D, Fremont, CA) attached to the eyepiece oí a surgical dissecting microscope (Zeiss Op-Mi6, Oberkochen, West Gernlany) displayed on a 25-inch video monitor (NEC, Melville, NY). The videotaped images were digitized into a 200 MHz personal computer (Gateway, North Sioux, City, SD) at a resolution of1500 X 1125 pixels using a Snappy Video Snapshot-capturing device (Play, Inc., Rancho Cordova, CA). The digitized images were imported into a data analysis program (OPTIMAS 4.0, Bioscan Inc., Edmonds, W A) where wound area measurements were made by tracing the wound margins with a fine-resolution computer mouse. The wound margins to be traced were determined by comparing the chromatic differential of the wound with the surrounding tissue. The area that was traced then provided a calculation of the area within the traced boundaries. The same investigator performed all wound area tracings.
Histology
Histologic examination of excised wounds was performed by light microscopy. Thin sections of experimental and control wounds were stained with hematoxylin and eosin. 
Experimental Groups and Statistical Analysis
Tbree experimental designs were used to determine the effects that TNP-470 has upon the rate of wound closure. First, we compared the effects of three concentrations of TNP-470 (5.0, 0.5, and 0.05 mg/kg) administered subcutaneously into the femoral triangle in two dosing regimens (Days O, 2, and 4 or Days O through 6). Second, we sought to see if combined administration of minocycline would augment fue effects ofTNP-470 on wound healing. Third, we sought to reverse the effects ofTNP-470 by concurrent administration of exogenous bFGF (See Table 1 nificant decreases in the rate of wound closure for all concentration groups compared to the control groups (P < 0.05) (Fig. 1) . Additionally, significant difIerences were observed among the concentration groups. Specifically, the 5.0 mg/kg concentration group had wound areas that were larger than the 0.5 mg/kg concentration group on Days 14 through 16, and larger than the 0.05 mg/kg concentration group on Days 2 through 16 (P < 0.05). Furthermore, the 0.5 mg/kg concentration group animals had wound areas that were significantly larger than the 0.05 mg/kg concentration group on Days 2 through 4 (P < 0.05). The highest concentration ofTNP-470 (5.0 mg/kg) resulted in the greatest difIerente in average wound area, yielding wounds that were 20.4% larger than the controls over fue duration ofthe study. The 0.5 mg/kg and 0.05 mg/kg concentration groups yielded average wound areas tbat exceeded the controls, by 13 and 9.1%, respectively, over the duration of the study. Histologic examination of the 5.0 mg/kg concentration group versus the vehicle control using H&E staining revealed a markedly delayed rate ofwound healing in the animals treated with TNP-470 (Figs. 2 and 3) . Specifically, this delay in wound heal-RESULTS N o significant differences were measured between the weights of experimental and control groups at any point of the study for either dosing regimen (Student's t test). AlI animal groups lost weight initially; however, all groups had regained the lost weight by Day 16. No differences were noted between the experimental and control groups of either dosing regimen regarding the respiratory rate, heart rate, or tolerance of anesthesia.
TNP-470 alone. Analysis of the data from the first dosing regimen (Days O, 2, and 4) revealed significant differences in wound aTeas, dependent upon the concentration of TNP-470 administered. There were sig- The effect ofcombined administration ofsystemic TNP-470 and topical bFGF on the rate ofwound healing. TNP-470 and its vehicle control were administered on Days O, 2, and 4, while bFGF and its vehicle control were administered on Days O, 1, and 2. TNP-470 alone resulted in a significant (P < 0005) decrease in the rate ofwound healing, while bFGF alone resulted in a significant (P < 0005) increase in the rate of healing versus the vehicle contraIgo In contrast, combined administration of TNP-470 and bFGF resulted in wound areas that were not significantly different versus the vehicle contraIgo Error bars are based on standard error measurementso gauze with a subsequent lowering ofthe bFGF concentration at the wound Bite. Statistical analysis has demonstrated that there is no significant difference in the effect of a 5.0 mg/kg concentration of TNP-470 when administered with petrolatum gauze or Duoderm gel as the primary dressing. Also, each experiment that was conducted had an appropriate control group for statistical comparison against the experimental groups. Both primary dressings (petrolatum gauze and Duoderm gel) serve to provide a moist wound healing environment that has been demonstrated to facilitate wound healing and ease dressing changes. DISCUSSION Our results show that TNP-470 is capable of exhibiting a dose-dependent inhibition of murine cutaneous wound healing by secondary intention. In our study, the greatest effect was obtained by administration of a 5.0 mg/kg clase, which yielded wound areas that were more than 20% larger than control wounds. Our largest clase was below the maximum tolerated clase of 6 mg/kg and the lethal clase of 256 mg/kg [personal communication with TAP Holdings Inc., Deerfield, IL]. We viewed no significant difference in the physiologic parameters between experimental and control groups, suggesting that TNP-470 was capable of modulating wound healing via distant subcutaneous delivery with no noticeable systemic toxicity. We believe this has significant implications in several areas. First, TNP-470 is currently undergoing clinical trials in the treatment of several diseases. It could be anticipated that many patients potentially could benefit from the use of this agent to control their disease. These patients would undoubtedly be subject to wound healing problems from a variety of sources, including surgical intervention to further eradicate disease, that could be potentially affected by treatment with TNP-470. Secondly, there are situations in which excessive wound healing leads to an unappealing aesthetic results or functional disability. TNP-470 may be of benefit in those special situations.
We made two attempts to increase TNP-470's effect on wound healing without success. Daily therapy showed little advantage ayer alternate-day therapy within the first 6 days. This is not surprising when one considers that the half-life of TNP-470's primary metabolite is 48 h [personal communication with TAP Holdings Inc., Deerfield, IL]. Further, an attempt to augment the wound closure inhibition of TNP-470 by coadministration with intraperitoneal..~d oral minocycline was unsuccessful. A possible réason for minocycline's lack of success may be that its ability to augment TNP-470 is limited to its known effect on neoplastic disease. .
The final phase of our experiment showed that coadministration of TNP-470 given systemically along with exogenous bFGF given locally yielded rates of wound cIosure that were not significantIy different when compar~d with those of contraigo This impIies that bFGF can reverse TNP-470-induced inhibition ofwoundhealing. This benefit would certainIy be useful in the cIinical setting where bFGF could be administered topically to cutaneous wounds to normalize the rate of wound cIosure in a patient who is receiving TNP-470 as a therapeutic agent to treat a neoplastic disease. Basic FGF is considered the prototypical angiogenic agent, in which direct induction of capillary sprouts in vitro and in vivo models of angiogenesis has been demonstrated [16, 17] . Interactions between TNP-470 and bFGF have been previously described [8, 11] . TNP-470 has be en showed to potentially inhibit endothelial cell proIiferation induced by both bFGF and vascuIar endothelial growth factor (VEGF) [18] . Also, the growth of bFGF transfected MCF-7 breast carcinoma cells is inhibited by treatment with TNP-470 [19, 20] . Mechanisms underIying the angiogenic inhibitory properties ofTNP-470 have been recentIy eIucidated by two independent Iaboratories [21, 22] . TNP-470 has been shown to bind to a metalloprotease, methionine aminopepticlase (Met AP-2). The inhibition ofMet AP-2 enzymatic activity appears to be responsible for the antiproliferative effects of TNP-470. However, the exact nature of the interaction between bFGF and TNP-470 awaits further cIarification.
